Results 51 to 60 of about 1,761 (189)

Évaluation du vaccin Shingrix contre le Zona

, 2022
Le zona est une maladie douloureuse provoquée par une réactivation du virus de la varicelle. Dans la plupart des cas, il guérit spontanément en 2 à 4 semaines. Il peut toutefois avoir des complications, comme la névralgie post-herpétique (10 à 20 % des cas de zona), ou d’autres complications plus rares mais aussi plus graves.
Dominique, Roberfroid, Zeevaert, Renate, Maertens de Noordhout, Charline, Thiry, Nancy   +3 more
openaire   +1 more source

Shingrix Vaccine and Guillain-Barre syndrome: a case report

RRNMF Neuromuscular Journal, 2020
   
Werdah Zafar, Hunain Aslam, Lakshmi Digala, Raghav Govindarajan   +3 more
openaire   +2 more sources

Short‐Term Safety and Adverse Event Risk Profiles for SARS‐CoV‐2 Booster Vaccine Doses in Australian Adults: A Survey Study

Medical Journal of Australia, Volume 224, Issue 6, June 2026.
ABSTRACT Objective This study quantifies the short‐term risk profiles of seven severe acute respiratory syndrome coronavirus 2 virus (SARS‐CoV‐2) vaccines—Comirnaty Bivalent BA.1, Comirnaty Bivalent BA.4‐5, Comirnaty XBB.1.5, Spikevax Bivalent BA.1, Spikevax Bivalent BA.4‐5, Spikevax XBB.1.5 and Nuvaxovid—administered as booster doses in Australia ...
Evelyn Tay, Michael Dymock, Lucy Dawes, Lucy Deng, Thuy Nguyen, Alan Leeb, Julie A. Marsh, Nicholas Wood, Kristine Macartney, Thomas L. Snelling   +9 more
wiley   +1 more source

Immunopotentiation by Natural Extracts: Mechanisms and Applications in Influenza Vaccine Adjuvant Development

Food Science &Nutrition, Volume 14, Issue 5, May 2026.
Natural Extracts as Candidate Influenza Vaccine Adjuvants. Seasonal influenza vaccines face limitations due to viral mutations and low efficacy in vulnerable populations. Traditional adjuvants often have safety or immune‐activation constraints, leading to increased interest in natural extracts from plants, marine organisms, and fungi.
Thi Len Ho, Eun‐Ju Ko
wiley   +1 more source

Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors

npj Vaccines
Intratumoral (IT) immunotherapy can stimulate the tumor microenvironment and enhance anti-tumor immunity. We investigated IT delivery of three licensed viral vaccines—Shingrix (VZV shingles), Gardasil-9 (HPV), and Spikevax (SARS-CoV-2)—in prevaccinated ...
Shiv K. Sethi, Claire E. Bradley, Lukas Bialkowski, Yuk Ying Pang, Cynthia D. Thompson, John T. Schiller, Nicolas Çuburu   +6 more
doaj   +1 more source

A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates

Frontiers in Immunology
Herpes zoster (HZ), also known as shingles, remains a significant global health issue and most commonly seen in elderly individuals with an early exposure history to varicella-zoster virus (VZV).
Yuanyuan Li, Siyu Tian, Yuanbao Ai, Zhulong Hu, Chao Ma, Meijuan Fu, Zhenqian Xu, Yan Li, Shuyun Liu, Yongjuan Zou, Yu Zhou, Jing Jin   +11 more
doaj   +1 more source

Herpes Zoster Vaccine Awareness and Uptake Among Older Adults in Saudi Arabia: Insights for Public Health, Preventive Medicine, and Primary Care Practice

Journal of General and Family Medicine, Volume 27, Issue 3, May 2026.
ABSTRACT Background/Objectives Complications from Herpes Zoster (HZ) are common among older adults and immunosuppressed populations. The HZ vaccine is a clinically and financially superior alternative to antiviral medications. However, a knowledge gap exists within the population regarding HZ and the vaccine.
Adam F. Aldhawyan, Mohammed A. BuSaad, Hasan M. Alswiket, Abdullah M. Alradhi, Ryad F. Alamry, Fadel A. Almulla, Amjad Z. Boarish, Reema J. Alghamdi, Abdullatif K. Althunyan, Amani M. AlQarni   +9 more
wiley   +1 more source

Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval

, 2022
Background: Vaccinations have the potential to significantly lower the burden of disease for many major infections in the high-risk population of hematological and oncological patients.
Trostdorf, Katrin, Reinwald, Mark, Kiderlen, Til Ramón, Til Ramón Kiderlen, Arne Salomon, Mark Reinwald, Maike de Wit, Delmastro, Nicola, Nicola Delmastro, de Wit, Maike, Katrin Trostdorf, Salomon, Arne   +11 more
core   +1 more source

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

Pediatric Dermatology, Volume 43, Issue 3, Page 706-710, May/June 2026.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet, Clément Pruvot, Zoé Manssens, Wadih Abou‐Chahla, Sébastien Buche   +4 more
wiley   +1 more source

Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination

Vaccines, 2022
Adjuvants can increase the magnitude and durability of the immune response generated by the vaccine antigen. Aluminum salts (Alum) remain the main adjuvant licensed for human use. A few new adjuvants have been licensed for use in human vaccines since the
Noopur Bhatnagar, Ki-Hye Kim, Jeeva Subbiah, Bo Ryoung Park, Pengfei Wang, Harvinder Singh Gill, Bao-Zhong Wang, Sang-Moo Kang   +7 more
doaj   +1 more source